Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Cancer
|
December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
S J DeNardo, L A Kroger, K R Lamborn, et al.
Journal of Clinical Apheresis
|
January 1, 1994
Sequential transplants using mobilized peripheral blood progenitor cells
R Ghalie, C M Richman, J G Bender, et al.
Anticancer Research
|
January 19, 1999
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol
S J Denardo, C M Richman, D L Kukis, et al.
Anticancer Research
|
May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
S J Denardo, C M Richman, D S Goldstein, et al.
Cancer
|
August 15, 1980
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma
L M Parker, C T Griffiths, R A Yankee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 1, 1997
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial
S J DeNardo, E L Kramer, R T O'Donnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1994
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation
R Ghalie, C M Richman, S S Adler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts
G L DeNardo, L A Kroger, C F Meares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A
C M Richman, S J DeNardo, R T O'Donnell, et al.
Anticancer Research
|
May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody
S J Denardo, L F O'Grady, C M Richman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Cancer
|
December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
S J DeNardo, L A Kroger, K R Lamborn, et al.
Journal of Clinical Apheresis
|
January 1, 1994
Sequential transplants using mobilized peripheral blood progenitor cells
R Ghalie, C M Richman, J G Bender, et al.
Anticancer Research
|
January 19, 1999
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol
S J Denardo, C M Richman, D L Kukis, et al.
Anticancer Research
|
May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
S J Denardo, C M Richman, D S Goldstein, et al.
Cancer
|
August 15, 1980
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma
L M Parker, C T Griffiths, R A Yankee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 1, 1997
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial
S J DeNardo, E L Kramer, R T O'Donnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1994
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation
R Ghalie, C M Richman, S S Adler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts
G L DeNardo, L A Kroger, C F Meares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A
C M Richman, S J DeNardo, R T O'Donnell, et al.
Anticancer Research
|
May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody
S J Denardo, L F O'Grady, C M Richman, et al.
Page
of 5